Antigen News and Research

RSS

AI-Guided Protein Engineering Creates Smart Receptors for Cancer Immunotherapy

Cancer immunotherapy, especially using T cells, is showing a lot of promise in treating blood cancers. Bioengineered T cells, especially those equipped with chimeric antigen receptors (CAR-T cells), have revolutionized cancer treatment.

29 Oct 2025

Scientists Reveal How Nanovaccines Boost the Immune Fight Against Aggressive Breast Cancers

Nanovaccines show promise in breast cancer therapy, enhancing immune activation and targeting cold tumors, particularly in challenging triple-negative cases.

24 Oct 2025

Cracking the Code of T Cell Expansion Inside Tumors

The ability of immune cells-particularly CD8+ T cells-to launch a rapid burst of proliferation inside tumors is key to the success of modern day cancer immunotherapies.

22 Oct 2025

GlyTR Therapeutics Unveils Groundbreaking Glycan-Targeting Cancer Immunotherapy

GlyTR Therapeutics, a biotech company pioneering development of glycan-targeting cancer immunotherapies, announced the publication of its foundational technology in the journal, Cell.

14 Oct 2025

RfaH Identified as Key to Bacterial Survival in Hostile Environments

Researchers at Umeå University have identified a key molecular player that helps bacteria survive the hostile environment inside the body.

10 Oct 2025

Study Reveals How Lymphatic Cells Preserve Immune Memory

A study published today in Nature Communications describes how lymphatic endothelial cells assist in generating robust immune memory, offering new insights into how the immune system functions.

26 Sep 2025

Pre-Wired T Cells Offer a New Path for Cancer Vaccines

A team of immunologists at the University of Massachusetts Amherst has turned what we know about T-cells, one of the most important parts of the body's immune system, on its head, opening the door to next-generation cancer vaccines.

13 Sep 2025

FSH: A Promising Biomarker For Endometrioid Ovarian Cancer?

Research reveals FSHB and FSH as key biomarkers for endometrioid ovarian cancer, offering insights into early detection and potential drug repurposing.

4 Sep 2025

New Research Explains How Alcohol Inhibits Gut Health

Alcohol-associated liver disease (ALD) is a leading cause of liver transplantation and mortality globally, and its effect is only increasing.

27 Aug 2025

Automated 15-minute, Aseptic Micro-Sampling of T Cells

Auto-CeSS is an automated system for aseptic 30 μL sample collection, enhancing process monitoring and reducing contamination in cell therapy manufacturing.

13 Aug 2025

CD276 Antibody Strategy Offers Hope For Immune-Resistant Lung Tumors

The study highlights 8H8_SDIE's role in activating NK cells against NSCLC, offering a new strategy for patients resistant to conventional immunotherapies.

6 Aug 2025

UCLA Researchers Reprogram Stem Cells to Produce Continuous Cancer-Fighting T Cells

In a first-of-its-kind clinical trial, UCLA scientists have shown it's possible to reprogram a patient's blood-forming stem cells to generate a continuous supply of functional T cells, the immune system's most powerful cancer-killing agents.

5 Aug 2025

Elegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Manufacturing Process for RNA-based Personalized Cancer Therapeutics

Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry's first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics (PCTs).

From Elegen 15 Jul 2025

UAB Identifies Six Novel Subsets, Reshaping Immune Knowledge

The study highlights T-bet's importance in memory B cells, essential for rapid antibody production and sustained immune defense against influenza.

14 Jul 2025

Engineered Macrophages Enable CAR T Cells to Overcome Glioblastoma Barriers

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and Luigi Naldini, has unveiled a powerful strategy to rejuvenate the effectiveness of chimeric antigen receptor (CAR) T cell therapy against glioblastoma, one of the most lethal and treatment-resistant brain tumors.

4 Jul 2025